Hum Reprod:早期流产:米索前列醇单次给药or多次给药?

2017-06-28 顾歆纯 环球医学资讯

2017年6月,发表在《Hum Reprod》的一项由以色列科学家进行的随机临床试验,比较了米索前列醇单次给药和多次给药用于早期终止妊娠的效果。

2017年6月,发表在《Hum Reprod》的一项由以色列科学家进行的随机临床试验,比较了米索前列醇单次给药和多次给药用于早期终止妊娠的效果。

研究问题:多次使用米索前列醇会增加早期终止妊娠的成功率吗?

总结回答:多次使用米索前列醇不能增加治疗成功率,且与更多止痛剂使用相关。

已知信息:米索前列醇降低手术清除的需求,并缩短了早期流产患者彻底清除的时间。但是,多次使用米索前列醇的影响仍不清楚。

研究设计、样本大小和持续时间:在一家三级医院开展一项随机临床试验,招募2015年8月至2016年6月因需要早期流产(<12周)寻求药物治疗的女性。160例患者的样本量足以监测治疗成功降低30%。

参与者/材料、地点和方法:参与者在第1天经阴道接受米索前列醇800 μg,随后被随机分配到两组:在第8天评价单次给药组的患者。在第4天评价多次给药组的患者,当她们需要时重复给一次药,安排在第8天再次进行评价。如果在第8天没有完全清除(子宫内膜厚度>15 mm或阴道彩超中显示有妊娠囊),则参与者进行手术清除。主要结局为终止妊娠成功,定义为直至第8天不需要手术干预。

主要结果和可能性的影响:最终分析纳入了单次给药组87例参与者和多次给药组84例参与者,其中41例(48.8%)接受了第二次给药。单次给药组中67例(77%)患者治疗成功,多次给药组中64例(76%)患者治疗成功(RR 0.98;95% CI 0.83~1.16;P=0.89)。多次给药组患者报告非处方止痛药使用较多(82.1% vs 69.0%,P=0.04)。

局限性和需要警戒的理由:该研究没有设盲,且研究人员对完全清除的定义可能具有争议。由于一些患者在第4天实现了完全清除,而一些患者在第8天之前经历了紧急D&C,所有患者的随访时间不一致。然而,这未影响主要结局。

发现的更广泛意义:结果表明,由于成功率相当且止痛药需求方面的有利结局,单次给药方案优于多次给药方案。

研究资金/利益冲突:该研究未接受资金。研究者声明没有利益冲突。

试验注册号:ClinicalTrials.gov(NCT02515604)。

试验注册日期:2015年8月。

纳入首例患者的日期:2015年8月。

原始出处:
Mizrachi, Y., et al.Single versus repeat doses of misoprostol for treatment of early pregnancy loss-a randomized clinical trial.Hum Reprod. 2017 Jun 1;32(6):1202-1207. doi: 10.1093/humrep/dex074.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1934066, encodeId=e9381934066b2, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Fri Mar 30 04:15:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601883, encodeId=a7c11601883cf, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jun 30 05:15:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216830, encodeId=700c216830cd, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Thu Jun 29 21:41:24 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216364, encodeId=8c952163646f, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 28 15:01:46 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1934066, encodeId=e9381934066b2, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Fri Mar 30 04:15:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601883, encodeId=a7c11601883cf, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jun 30 05:15:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216830, encodeId=700c216830cd, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Thu Jun 29 21:41:24 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216364, encodeId=8c952163646f, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 28 15:01:46 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
    2017-06-30 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1934066, encodeId=e9381934066b2, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Fri Mar 30 04:15:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601883, encodeId=a7c11601883cf, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jun 30 05:15:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216830, encodeId=700c216830cd, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Thu Jun 29 21:41:24 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216364, encodeId=8c952163646f, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 28 15:01:46 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
    2017-06-29 thlabcde

    好东西学习了!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1934066, encodeId=e9381934066b2, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Fri Mar 30 04:15:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601883, encodeId=a7c11601883cf, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jun 30 05:15:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216830, encodeId=700c216830cd, content=好东西学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Thu Jun 29 21:41:24 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216364, encodeId=8c952163646f, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 28 15:01:46 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
    2017-06-28 Y—xianghai

    学习了新知识

    0